Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib plus R-CHOP for newly diagnosed diffuse large B-cell lymphoma
ISRCTN14251143Phase 2Active, not recruiting
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Oct 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of acalabrutinib in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Progression-free survival at 2 years. Started Oct 2021; status: active, not recruiting.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ISRCTN14251143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14251143.